AbbVie: Outstanding Portfolio Performance Continues

Aug. 15, 2022 3:52 PM ETAbbVie Inc. (ABBV) StockABBV22 Comments
Cappuccino Finance
3.24K Followers

Summary

  • Skyrizi and Rinvoq are performing exceptionally (expected to deliver $7.5 B sales this year).
  • Neuroscience, aesthetics, and oncology are showing strong growth as well.
  • AbbVie is swimming in cash.

3d render. Pharmaceutical manufacture background with glass bottles with clear liquid on automatic conveyor line. COVID-19 mRNA vaccine production platform.

wacomka

Investment Thesis

AbbVie (NYSE:ABBV) is a global, diversified biopharmaceutical company that has a portfolio of drugs in leadership positions across immunology, oncology, neuroscience, and aesthetics. Patent protection and technological superiority have created an economic moat that allows them to grow while generating a

This article was written by

3.24K Followers
I believe in fundamental analysis and disciplined market research. I have strong quant background with a Ph.D. (Chemical Engineering, University of California, Santa Barbara) in model predictive control and an MBA (Jones School of Business, Rice University). My primary focus is to identify 1) small cap companies with strong fundamentals and growth potential, 2) large cap companies going through temporary set-backs, and 3) stable companies with solid dividend yields and growth potential.

Analyst’s Disclosure:I/we have a beneficial long position in the shares of ABBV either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

About ABBV Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on ABBV

Related Stocks

SymbolLast Price% Chg
ABBV
--